Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review Article

Antivascular and Antitumor Activities of Liposome-associated Drugs

ROBERT M. STRAUBINGER, ROBERT D. ARNOLD, RONG ZHOU, RICHARD MAZURCHUK and JEANINE E. SLACK
Anticancer Research March 2004, 24 (2A) 397-404;
ROBERT M. STRAUBINGER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERT D. ARNOLD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RONG ZHOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICHARD MAZURCHUK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEANINE E. SLACK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Particulate drug carriers offer unique opportunities to improve tumor therapy through several different mechanisms. Liposomes may (1) assist in formulation of poorly-soluble therapeutic agents, (2) provide a slow-release vehicle to achieve pharmacokinetic profiles that maximize the therapeutic index, or (3) behave as long-circulating nano-particulates that can extravasate in the hyperpermeable regions of tumor vasculature. For paclitaxel, liposomes provide an aid to formulation. In the intracranial rat 9L brain tumor model, paclitaxel liposomes reduced dose-limiting toxicity and mediated a 40% increase in median survival. Free drug did not extend survival. Doxorubicin entrapped within sterically-stabilized liposomes (SSL-DXR) represents a long-circulating formulation that can extravasate within tumors and enhance drug deposition. Repetitive dosing with SSL-DXR mediated a 30% extension in median lifespan of animals bearing advanced 9L tumors. Fluorescence microscopic imaging revealed non-uniform, sporadic deposition of liposomes within the tumor. Magnetic resonance imaging showed that repetitive dosing with SSL-DXR, but not free drug, resulted in vascular collapse and microhemorrhage within tumors. Exploiting this antivascular effect may provide a new means to enhance tumor therapy, and suggests the utility of combination therapy with agents such as paclitaxel that have antiangiogenic effects on tumors.

Footnotes

  • ↵* Current address: Department of Radiology, University of Pennsylvania, B1 Stellar Chance Labs, 422 Currie Blvd. Philadelphia, PA 19104-6100, U.S.A.

    • Received September 17, 2003.
    • Accepted January 5, 2004.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (2A)
Anticancer Research
Vol. 24, Issue 2A
March-April 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antivascular and Antitumor Activities of Liposome-associated Drugs
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Antivascular and Antitumor Activities of Liposome-associated Drugs
ROBERT M. STRAUBINGER, ROBERT D. ARNOLD, RONG ZHOU, RICHARD MAZURCHUK, JEANINE E. SLACK
Anticancer Research Mar 2004, 24 (2A) 397-404;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Antivascular and Antitumor Activities of Liposome-associated Drugs
ROBERT M. STRAUBINGER, ROBERT D. ARNOLD, RONG ZHOU, RICHARD MAZURCHUK, JEANINE E. SLACK
Anticancer Research Mar 2004, 24 (2A) 397-404;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
  • Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy
  • 9L Gliosarcoma Cell Proliferation and Tumor Growth in Rats Are Suppressed by N-Hydroxy-N'-(4-butyl-2-methylphenol) Formamidine (HET0016), a Selective Inhibitor of CYP4A
  • BJR Review of the Year - 2004
  • Google Scholar

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire